Table II.
Evidence-based probiotic lactobacilli according to randomized double-blind placebo-controlled studies (adapted from 68,69).
| Strain affiliation | Licensing enterprise | Published clinical evidence (reference no.) |
|---|---|---|
| Lactobacillus acidophilus La5 | Chr. Hansen, Denmark | Suppression of Helicobacter pylori infection (78) |
| L. acidophilus L1 | Campina Melkunie, Holland | Blood cholesterol-lowering effect (79) |
| Lactobacillus johnsonii LA1 | Nestle, Switzerland | Suppression of Helicobacter pylori colonization in children (80) |
| Lactobacillus gasseri OLI 27168 | Meij Milk Products, Tokyo, Japan | Suppression of Helicobacter pylori infection (81) |
| Lactobacillus casei Shirota | Yakult, Japan | Reduction of constipation, reduced proteolytic activity of IMB (82,83) |
| L. casei DN1 14001 | Danone, France | Reduction of winter infections in elderly (84), diarrhea and respiratory infections in adults (85,86). |
| Lactobacillus paracasei LP-33 | Un-President Enterprise Corp., Tainan, Taiwan | Reduction of allergic rhinitis (87) |
| Lactobacillus rhamnosus GG ATCC 53103 | Valio, Finland | Reduction of diarrhoeal infections and allergy (88–92); increased expression of immune response genes (93) |
| L. rhamnosus GR-1 and L. reuteri RC-14 | Chr. Hansen, Denmark | Reduction of diarrhoeal infections in children (94) |
| L. rhamnosus HN001 | Danisco, Denmark | Enhanced immunity of consumers (95) |
| Lactobacillus plantarum 299V | Probi, Sweden | Reduction of infectious complications in transplantation patients; decrease of intestinal permeability (96) |
| Lactobacillus brevis CD2 | VSL Pharmaceuticals, Inc., Fort Lauderdale, FL, USA | Reduction of Helicobacter pylori infection, reduction of levels of polyamines in gastric mucosa (97) |
| Lactobacillus reuteri ATCC 55730 | BioGaia, Sweden | Reduction of diarrhoeal infections, enhancement of consumers' immunity (98,99) |
| Lactobacillus fermentum ME-3 DSM 14241 | AS Tere, Estonia | Anti-atherogenic effect due to increase of antioxidative activity indices, decrease of GSSG/GSH ratio and oxLDL of sera (100–102) |
IMB, intestinal microbiota; GSSG/GSH ratio, glutathione redox ratio; oxLDL, oxidized low-density lipoprotein.